Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells
- 727 Downloads
The immune system has evolved regulatory mechanisms to control immune responses to self-antigens. Regulatory T (Treg) cells play a pivotal role in maintaining immune tolerance, but tumour growth is associated with local immunosuppression, which can subvert effector immune responses. Indeed, the induction and recruitment of Treg cells by tumours is a major barrier in the development of effective immunotherapeutics and vaccines against cancer. Retinoic acid (RA) has been shown to promote conversion of naïve T cells into Treg cells. This study addresses the hypothesis that blocking RA receptor alpha (RARα) may enhance the efficacy of a tumour vaccine by inhibiting the induction of Treg cells. We found that RA significantly enhanced TGF-β-induced expression of Foxp3 on naïve and committed T cells in vitro and that this was blocked by an antagonist of RARα (RARi). In addition, RARi significantly suppressed TGF-β and IL-10 and enhanced IL-12 production by dendritic cells (DC) in response to killed tumour cells or TLR agonists. Furthermore, RARi augmented the efficacy of an antigen-pulsed and TLR-activated DC vaccine, significantly attenuating growth of B16 tumours in vivo and enhancing survival of mice. This protective effect was associated with significant reduction in tumour-infiltrating FoxP3+ and IL-10+ Treg cells and a corresponding increase in tumour-infiltrating CD4+ and CD8+ T cells that secreted IFN-γ. Our findings demonstrate that RARα is an important target for the development of effective anti-tumour immunotherapeutics and for improving the efficacy of cancer vaccines.
KeywordsTumour immunity Retinoic acid Regulatory T cells TGF-β Dendritic cell vaccine
This work was supported by Science Foundation Ireland (SFI) PI grants (06/IN.1/B87 and 11/PI/1-36) to Kingston Mills.
Conflict of interest
Kingston Mills is a co-founder and shareholder in Opsona Therapeutics Ltd and TriMod Therapeutics Ltd, university spin-out companies involved in the development of immunotherapeutics. All other authors do not have any conflict of interest.
- 2.Molenaar R, Knippenberg M, Goverse G, Olivier BJ, de Vos AF, O’Toole T, Mebius RE (2011) Expression of retinaldehyde dehydrogenase enzymes in mucosal dendritic cells and gut-draining lymph node stromal cells is controlled by dietary vitamin A. J Immunol 186:1934–1942. doi: 10.4049/jimmunol.1001672 PubMedCrossRefGoogle Scholar
- 7.Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F (2007) A functionally specialized population of mucosal CD103 + DCs induces Foxp3 + regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 204:1757–1764. doi: 10.1084/jem.20070590 PubMedCrossRefGoogle Scholar
- 17.Coe D, Addey C, White M, Simpson E, Dyson J, Chai JG (2010) The roles of antigen-specificity, responsiveness to transforming growth factor-beta and antigen-presenting cell subsets in tumour-induced expansion of regulatory T cells. Immunology 131:556–569. doi: 10.1111/j.1365-2567.2010.03328.x PubMedCrossRefGoogle Scholar
- 20.Marshall NA, Galvin KC, Corcoran AM, Boon L, Higgs R, Mills KH (2012) Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-gamma+ IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res 72:581–591. doi: 10.1158/0008-5472.CAN-11-0307 PubMedCrossRefGoogle Scholar